

南區上消化道癌症治療研討會

時間: 111 年 10 月 15 (六) 14:00-17:00.

地點: 高雄漢來大飯店 15F 會議廳

Time	Topic	Speaker	Moderator
14:00-14:30	Registration		
14:30-14:40	Opening	陳立宗 教授 高醫附設 / 國衛院癌研所	
14:40-15:10	The overview of treatment in duodenal cancer	姜乃榕 醫師 台北榮總	陳以書 主任 高雄榮總
15:10-15:40	Treatment advancement in APC	蘇勇曄 醫師 成大醫院	邱泰然 醫師 高雄長庚
15:40-16:00	Coffee break		
16:00-16:40	Pemigatinib in cholangiocarcinoma with FGFR2 fusions or rearrangements	郭雨萱 醫師 奇美醫院	顏家瑞 主任 成大醫院
16:40-17:00	Discussion & Closing	饒坤銘 副院長 義大癌治療醫院	

主辦單位: 高雄市南屏癌症防治衛教學會

課程摘要:

The overview of treatment in duodenal cancer

Small bowel adenocarcinoma (SBA) is a rare malignancy with worse prognosis compared to other cancers of the gastrointestinal tract. Of which, duodenal cancer occurs in the first part of small intestine (duodenum). The four main types of duodenal cancer include adenocarcinoma, carcinoid tumor, lymphoma and sarcoma.

If the primary site locates in the duodenum, an extensive operation with Whipple procedure (or pancreaticoduodenectomy) is typically applied for resectable disease.

For locally advanced or metastatic disease, chemotherapy remains the standard treatment, which contains fluoropyrimidine, oxaliplatin or irinotecan. The potentially targetable genomic alterations of SBA have recently identified in a large subset of patients. These targetable alterations could potentially promote new therapeutic options that shape clinical management and establish new standards for the SBA.

Treatment advancement in APC

Owing to the delay in diagnosis and lack of effective therapeutic regimens, PDAC remains one of the deadliest cancers over the years. Both FOLFIRINOX (5-FU/LV, oxaliplatin and irinotecan) and Nab-P + Gem (nab-paclitaxel plus gemcitabine) have demonstrated significant survival benefit against gemcitabine in patients with metastatic pancreatic adenocarcinoma. For known being more toxic in Asian population, and late and limited reimbursement of both FOLFIRINOX and nab-P+Gem regimens for patients with metastatic diseases in Taiwan, our practice for LAPC has been largely relied on our own gemcitabine-based triplet chemotherapy regimens consisting of biweekly gemcitabine, oxaliplatin plus leucovorin modulated fluoropyrimidine, either 48 hour infusion of 5-FU/LV (the GOFL regimen) or oral S-1/LV (the SLOG regimen). Currently, we are evaluating the efficacy of Gemcitabine and Nab-paclitaxel in combination with S-1/LV (GASL) or Oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer in a multi-center phase 2 T5221 study.

Pemigatinib in cholangiocarcinoma with FGFR2 fusions or rearrangements

With the advancement of next generation sequencing (NGS), many actionable molecular aberrations were identified in patients with biliary tract cancers. Currently NGS on tumor samples was recommended for all patients with newly diagnosed intra-hepatic cholangiocarcinoma. For instance, fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, one of the most frequent genetic alternation in intrahepatic cholangiocarcinoma, has been a hot spot for targeted therapy development. Impressive results from phase II studies in pre-treated patients have confirmed that FGFR-inhibitors are a promising therapeutic option for this genetic alterations. In 2020, pemigatinib became the first FDA-approved targeted therapy for adults with previously treated locally advanced or metastatic cholangiocarcinoma based on a high response rate of 36% from FIGHT-202 study. A confirmatory phase III is on-going to confirm the efficacy of pemigatinib versus gemcitabine in combination with cisplatin in first-line treatment. Approval of pemigatinib was just the first step, since then two other targeted therapies for cholangiocarcinoma have been approved by FDA. More options are available and treatment landscape is changing.

講師介紹

姜乃榕

EDUCATION

2014/09~present Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan

1998/08~2005/07 M.D., National Defense Medical Center, Taipei, Taiwan

PROFESSIONAL EXPERIENCES

2020/04~present Assistant Investigator & Attending physician, National Institute of Cancer Research, National Health Research Institutes

2013/07~present Attending physician, National Institute of Cancer

Research, NHRI, Tainan, Taiwan and Division of Oncology-Hematology, Department of internal medicine, National Cheng Kung University hospital.

2010/09–2013/06 Fellowship, National Institute of Cancer Research, NHRI, Tainan, Taiwan.

2008/09–2010/08 Chief Resident, Division of Oncology-Hematology, Department of internal medicine, National Cheng Kung University hospital and National Institute of Cancer Research, NHRI, Taiwan.

2005/08–2008/08 Residency training, Department of Internal Medicine, VGH-TPE and National Institute of Cancer Research, NHRI, Taiwan.

蘇勇暉

Education

2005.08 – 2012.07	M.D., School of Medicine, Kaohsiung Medical University
2018.09 – present	Ph. D student, Institute of Clinical Medicine, College of Medicine, National Cheng Kung University

Board

2019	Certified doctor of Oncology
2017	Certified doctor of Internal Medicine
2016	Certification of Advanced Cardiovascular Life Support (ACLS)

Occupation and professional training

2020.05 – present	Attending physician, National Institute of Cancer Research, National Health Research Institute
2019.09 – present	Attending physician, Division of Medical Oncology, Department of Internal Medicine, National Cheng Kung University Hospital
2017.08 – 2019.08	Chief Resident / Fellowship of medical oncology, Division of Medical Oncology, Department of Internal Medicine, National Cheng Kung University Hospital
2015.09 – 2020.04	Resident, National Institute of Cancer Research, National Health Research Institute
2015.09 – 2017.07	Resident, Department of Internal Medicine, National Cheng Kung University Hospital
2014.08 – 2015.07	Resident, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung,

Taiwan
2013.08 – 2014.07 Post Graduate Year (PGY) Physicians, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
2012.08 – 2013.03 Compulsory Military Service, Reserve Officer (Second Lieutenant), ROC Air Force Combatant Command
2011.06 – 2012.05 Internship, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

Memberships:

2012 Formosan Medical Association
2017 Society of Internal Medicine, Taiwan, R.O.C.
2019 Taiwan Academy of Hospice Palliative Medicine
2019 Taiwan Oncology Society

郭雨萱

慈濟大學 醫學士 2004-05

經歷： 2011.8-

臺大醫院內科部 住院醫師 2004.7-2007.6

臺大醫院腫瘤醫學部 總醫師 2007.7-2010.6

臺大醫院雲林分院腫瘤醫學部 主治醫師 2010.7-2011.7

義大醫院血液腫瘤科 主治醫師 2011.8-2012.8

現任：奇美醫院血液腫瘤科 主治醫師 2012.9-

教育部部定助理教授